SpringerLink
Log in

Chemotherapy Induced Nausea and Vomiting

  • Chapter
  • First Online:
International Manual of Oncology Practice

  • 807 Accesses

Abstract

Oncology practitioners currently have very effective antiemetic agents in the form of 5-hydroxytryptamine-3 receptor antagonists, neurokinin-1 receptor antagonists, dexamethasone, and olanzapine for use in the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy. The choice of individual agents and the combination of agents should be dictated by the emetogenicity of the chemotherapy and patient risk factors. The available agents for the prevention of CINV appear to be safe and effective with few reported adverse events when used in the recommended doses.

The use of these agents in various clinical settings is described by established antiemetic guidelines from the Multinational Association of Supportive Care in Cancer and the European Society of Medical Oncology, the American Society of Clinical Oncology, and the National Comprehensive Cancer Network. These guidelines should be followed by practitioners in order to provide the highest possible quality of care for patients receiving chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Abbreviations

ASCO:

American Society of Clinical Oncology

CINV:

Chemotherapy-induced nausea and vomiting

CTZ:

Chemoreceptor trigger zone

FDA:

Food & Drug Administration

GI:

Gastrointestinal

5-HT3:

5-hydroxytryptamine-3

HEC:

Highly emetogenic chemotherapy

MEC:

Moderately emetogenic chemotherapy

MASCC:

Multinational Association of Supportive Care in Cancer

NCCN:

National Comprehensive Cancer Network

NTS:

Nucleus Tractus solitarius

NK-1:

Neurokinin-1

VAS:

Visual analogue scale

VC:

Vomiting Centre

References

  1. Bloechl-Daum B et al (2006) Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472–4478

    Article  CAS  PubMed  Google Scholar 

  2. Cohen L et al (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15:497–503

    Article  PubMed  Google Scholar 

  3. Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374:1356–1367

    Article  CAS  PubMed  Google Scholar 

  4. Grunberg SM (2004) Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment—how are we doing? J Support Oncol 2:1–10

    PubMed  Google Scholar 

  5. Broder MS et al (2014) The impact of 5HT3RA use on cost and utilization in patients with chemotherapy-induced nausea and vomiting: systematic review of the literature. Am Health Drug Benefits 7:171–182

    PubMed  PubMed Central  Google Scholar 

  6. Navari RM (2013) Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs 73:249–262

    Article  CAS  PubMed  Google Scholar 

  7. Navari RM (2014) Palonosetron for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother 15:2599–2608

    Article  CAS  PubMed  Google Scholar 

  8. Aapro M, Carides A, Rapoport BL (2015) Aprepitant and fosaprepitant: a ten-year review of efficacy and safety. Oncologist 20:450–458

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Navari RM (2015) Profile of netupitant/palonosetron fixed dose combination (NEPA) and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther 9:155–161

    CAS  PubMed  Google Scholar 

  10. Navari RM (2015) Rolapitant for the treatment of chemotherapy induced nausea and vomiting. Expert Rev Anticancer Ther 15:1127–1133

    Article  CAS  PubMed  Google Scholar 

  11. Navari RM et al (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 15:1285–1291

    Article  PubMed  Google Scholar 

  12. Tan L et al (2009) Clinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:1–7

    Article  CAS  Google Scholar 

  13. Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188–195

    Article  CAS  PubMed  Google Scholar 

  14. Navari RM et al (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375:134–142

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Mukhopadhyay S et al (2017) Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study. Support Care Cancer 25:145–154

    Article  PubMed  Google Scholar 

  16. Navari RM (2012) Treatment of chemotherapy-induced nausea. Commun Oncol 9:20–26

    Article  Google Scholar 

  17. Ng TL, Hutton B, Clemons M (2015) Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea? Oncologist 20:576–583

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Stern RM, Koch KL, Andrews PLR (2011) Nausea: mechanisms and management. Oxford University Press, New York

    Google Scholar 

  19. Molassiotis A et al (2017) MASCC/ESMO antiemetic guidelines: introduction to the 2016 guideline update. Support Care Cancer 25:267

    Article  CAS  PubMed  Google Scholar 

  20. Hesketh PJ et al (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:3240–3261

    Article  CAS  PubMed  Google Scholar 

  21. NCCN Clinical Practice Guidelines in Oncology version 2.2017. Antiemesis. National Comprehensive Cancer Network (NCCN) [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf. Accessed June, 2017

  22. Koga T, Fukuda H (1992) Neurons in the nucleus of the solitary tract mediating inputs from Vagal afferents and the area postrema in the pattern generator in the emetic act in dogs. Neurosci Res 14:366–379

    Article  Google Scholar 

  23. Yates BJ et al (1994) Organization of the vestibular inputs to nucleus tractus solitarius and adjacent structures in cat brain stem. Am J Phys 267:974–983

    Google Scholar 

  24. Simpson K, Spencer CM, McClellan KJ (2000) Topisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 59:1297–1315

    Article  CAS  PubMed  Google Scholar 

  25. Kimura E et al (1996) Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho 23:477–481

    CAS  PubMed  Google Scholar 

  26. Taguchi T et al (1999) Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer. Gan To Kagaku Ryoho 26:1163–1170

    CAS  PubMed  Google Scholar 

  27. Hesketh PJ (2000) Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Investig 18:163–173

    Article  CAS  Google Scholar 

  28. World Health Organization (2006) Dolasetron mesylate and serious cardiovascular reactions, vol 20. WHO Drug Information, p 185

    Google Scholar 

  29. U.S. Food and Drug Information. FDA drug safety communication: abnormal heart rhythms associated with use of anzemet (dolasetron mesylate) [online]. Available from URL: http://www.fda.gov/Drugs.DrugSafety/usm237081.htm. Accessed 15 June 2017

  30. Ondansetron [online], Available from URL: www.drugs.com/fda/ondansetron. Accessed 15 June July 2017

  31. Mason JW et al (2014) A randomized, placebo-controlled, four-period cross-over definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTC prolongation. Cancer Manag Res 6:183–189

    Google Scholar 

  32. Roila F et al (2005) Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 13:104–108

    Article  PubMed  Google Scholar 

  33. Geling O, Eichler H (2005) Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289–1294

    Article  CAS  PubMed  Google Scholar 

  34. Hickok JT et al (2005) 5-HT3 receptor antagonists versus perchlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomized controlled trial. Lancet Oncol 6:765–772

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Saito M et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for the prevention of nausea and vomiting during chemotherapy: a double-blind, double dummy, randomized, comparative phase III trial. Lancet Oncol 10:115–124

    Article  CAS  PubMed  Google Scholar 

  36. Warr DG et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822–2830

    Article  CAS  PubMed  Google Scholar 

  37. Boccia RV et al (2011) Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 19:1609–1617

    Article  PubMed  Google Scholar 

  38. Raftopoulos H et al (2015) Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double blind, noninferiority phase III trial. Support Care Cancer 23:723–732

    Article  PubMed  Google Scholar 

  39. Eisenberg P et al (2004) Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical study. Ann Oncol 15:330–337

    Article  CAS  PubMed  Google Scholar 

  40. Rojas C et al (2010) Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. J Pharmacol 626:193–199

    CAS  Google Scholar 

  41. Botrel T et al (2011) Efficacy of palonosetron compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic treatment: systematic review and meta-analysis. Support Care Cancer 19:823–832

    Article  PubMed  Google Scholar 

  42. Schwartzberg L et al (2014) Pooled analysis of phase III studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 22:469–477

    Article  PubMed  Google Scholar 

  43. Popovic M et al (2014) Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 22:1485–1497

    Article  Google Scholar 

  44. Yavas C et al (2012) Acute effect of palonosetron electrocardiographic parameters in cancer patients; a prospective study. Support Care Cancer 20:2343–2347

    Article  CAS  PubMed  Google Scholar 

  45. Aogi K et al (2012) A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy. Support Care Cancer 20:1507–1514

    Article  PubMed  Google Scholar 

  46. Roila F et al (2014) Aprepitant versus metoclopramide, both combined with dexamethasone, for the preventing cisplatin-induced delayed emesis: a randomized, double-blind study. J Clin Oncol 32(5s (suppl)):abstr 9503

    Article  Google Scholar 

  47. Navari RM, Nagy CK, Gray SE (2013) Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655–1663

    Article  PubMed  Google Scholar 

  48. European Medicine Agency Metoclopramide use recommendations, 26 July 2013. www.ema.europa.eu. Accessed 15 June 2017

  49. Diemunsch P, Grelot L (2000) Potential of substance P antagonists as antiemetics. Drugs 60:533–546

    Article  CAS  PubMed  Google Scholar 

  50. Sankhala KK et al (2009) Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Expert Opin Drug Metab Toxicol 12:1607–1614

    Article  CAS  Google Scholar 

  51. Hesketh PJ et al (2006) Combined data from two phase III trials of the NK-1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 14:354–360

    Article  CAS  PubMed  Google Scholar 

  52. Warr DG et al (2005) The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from two randomized, double-blind, placebo controlled trials. Eur J Cancer 41:1278–1285

    Article  CAS  PubMed  Google Scholar 

  53. Grote T et al (2006) Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol 4:403–408

    CAS  PubMed  Google Scholar 

  54. Navari RM (2007) Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs 16:1977–1985

    Article  CAS  PubMed  Google Scholar 

  55. Grunberg S et al (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol—EASE. J Clin Oncol 29:1495–1501

    Article  CAS  PubMed  Google Scholar 

  56. Leal AD et al (2014) Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy. Support Care Cancer 22:1313–1317

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Drug interactions of aprepitant [slide presentation]. Available at http://www.fda.gov/ohrms/dockets/ac/03/slides/3928s1_03_fda-jarugula.ppt. Accessed 9 June 2017

  58. Scientific discussion: this module reflects the initial scientific discussion for the approval of Emend. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Scientific_Discussion/human/000527/WC500026534.pdf. Accessed 9 June 2017

  59. Aapro MS, Walko CM (2010) Aprepitant: drug-drug interactions in perspective. Ann Oncol 21:2316–2323

    Article  CAS  PubMed  Google Scholar 

  60. Schmitt T et al (2014) Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol 32:3413–3420

    Article  CAS  PubMed  Google Scholar 

  61. Pielichowski W et al (2011) A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. Transplant Proc 43:3107–3110

    Article  CAS  PubMed  Google Scholar 

  62. Stiff PJ et al (2013) Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant 19:49–55

    Article  CAS  PubMed  Google Scholar 

  63. Svanberg A, Bergegard C (2015) Addition of aprepitant to standard antiemetic regimen continued for seven days after chemotherapy for stem cell transplantation provide significant reduction of vomiting. Oncologia 89:31–36

    Article  CAS  Google Scholar 

  64. Uchida M et al (2013) Effectiveness and safety of antiemetic aprepitant in Japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation. Biol Pharm Bull 36:819–824

    Article  CAS  PubMed  Google Scholar 

  65. Sakuri M et al (2014) Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan–based conditioning for allogeneic hematopoietic stem cell transplantation. Int J Hematol 99:457–462

    Article  CAS  Google Scholar 

  66. Bechtel T et al (2014) Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. Support Care Cancer 22:2911–2916

    Article  PubMed  Google Scholar 

  67. Einhorn LH et al (2017) 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 25:303–308

    Article  PubMed  Google Scholar 

  68. Ottoboni T et al (2017) Bioequivalence of HTX-019 (aprepitant IV)(Cinvanti) and fosaprepitant in healthy subjects. Hematology/Oncology Pharmacy Association Annual Conference, March 29–April 1, 2017, Anaheim, CA

    Google Scholar 

  69. Rizzi A et al (2012) In vitro and in vivo pharmacological characterization of the novel NK-1 receptor selective antagonist Netupitant. Peptides 37:86–97

    Article  CAS  PubMed  Google Scholar 

  70. Spinelli T, Calcagneli S, Giuliano C (2014) Netupitant PET imaging and ADME studies in humans. J Clin Pharmacol 54:97–108

    Article  CAS  PubMed  Google Scholar 

  71. National Cancer Institute Drug Dictionary. Available from http://www.cancer.gov/drugdictionary. Accessed 15 June 2017

  72. Hesketh PJ et al (2014) Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 25:1340–1346

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Aapro M et al (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328–1333

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Gralla RJ et al (2014) A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 25:1333–1339

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. FDA News Release. FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy. Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements. Accessed 9 June 2017

  76. Duffy RA et al (2012) Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK-1 receptor antagonist with centrally-mediated antiemetic effects in ferrets. Pharmacol Biochem Behav 102:95–100

    Article  CAS  PubMed  Google Scholar 

  77. Poma A et al (2013) Rolapitant and its major metabolite do not affect the pharmacokinetics of midazolam, a sensitive cytochrome P450 3A4 substrate. Support Care Cancer 21:S154. Abstract 441

    Google Scholar 

  78. Poma A et al (2014) Phase 1 positron emission tomography (PET) study of the receptor occupancy of rolapitant, a novel NK-1 receptor antagonist. J Clin Oncol 32:abstr e20690

    Article  Google Scholar 

  79. Rapoport B et al (2015) Study of rolapitant, a novel, long acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Support Care Cancer 23:3281–3288

    Article  PubMed  Google Scholar 

  80. Schwartzberg L et al (2015) Safety and efficacy assessment of rolapitant for the prevention of chemotherapy-induced nausea and vomiting following administration of moderately emetogenic chemotherapy in cancer patients in a randomized phase 3 trial. Lancet Oncol 16:1071–1078

    Article  CAS  PubMed  Google Scholar 

  81. Rapoport B et al (2015) Safety and efficacy assessment of rolapitant for the prevention of chemotherapy-induced nausea and vomiting following administration of cisplatin-based highly emetogenic chemotherapy in cancer patients in two randomized phase 3 trials. Lancet Oncol 16:1079–1089

    Article  CAS  PubMed  Google Scholar 

  82. dos Santos LV et al (2012) Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst 104:1280–1292

    Article  CAS  PubMed  Google Scholar 

  83. Zhang Y et al (2016) Neurokinin-1 receptor antagonist-based triple regimens in preventing chemotherapy-induced nausea and vomiting: a network meta-analysis. J Natl Cancer Inst 109:djw217. https://doi.org/10.1093/jnci/djw217

    Article  CAS  PubMed  Google Scholar 

  84. Vardy J et al Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 1999, 94:1011–1015

    Google Scholar 

  85. Celio L et al (2011) Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multi-center, phase III trial. Support Care Cancer 19:1217–1225

    Article  PubMed  Google Scholar 

  86. Aapro M et al (2010) Double-blind, randomized, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21:1083–1088

    Article  CAS  PubMed  Google Scholar 

  87. Fulton B, Goa KL (1999) Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53:281–298

    Article  Google Scholar 

  88. Kando JC et al (1997) Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia. Ann Pharmacother 31:1325–1334

    Article  CAS  PubMed  Google Scholar 

  89. Bymaster FP et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87–96

    Article  CAS  PubMed  Google Scholar 

  90. Stephenson CME, Pilowski LS (1999) Psychopharmacology of olanzapine: a review. Br J Psychiatry 174:52–58

    Article  Google Scholar 

  91. Petersen AB et al (2014) Adverse effects associated with high dose therapy in patients admitted to inpatient psychiatric care. Clin Toxicol 52:39–43

    Article  CAS  Google Scholar 

  92. Passik S et al (2004) A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients receiving chemotherapy. Cancer Investig 22:383–388

    Article  CAS  Google Scholar 

  93. Goldstein LE et al (1999) New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 40:438–443

    Article  CAS  PubMed  Google Scholar 

  94. Mizukami N et al (2014) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind placebo-controlled study. J Pain Symptom Manag 47:542–550

    Article  Google Scholar 

  95. Davis MP (2016) New therapies for antiemetic prophylaxis for chemotherapy. J Community Support Oncol 14:11–20

    Article  PubMed  Google Scholar 

  96. Irving G et al (2009) Efficacy and tolerability of gastric-retentive gabapentin for the treatment of post-herpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain 25:185–192

    Article  PubMed  Google Scholar 

  97. Guttuso T, Roscoe J, Griggs J (2003) Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet 361:1703–1705

    Article  CAS  PubMed  Google Scholar 

  98. Cruz FM et al (2011) Gabapentin for the prevention of chemotherapy-induced nausea and vomiting: a pilot study. Support Care Cancer 20:601–606

    Article  PubMed  Google Scholar 

  99. Barton DL et al (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120:3575–3583

    Article  CAS  PubMed  Google Scholar 

  100. Van Sickle MD et al (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310:329–332

    Article  CAS  PubMed  Google Scholar 

  101. Darmani NA (2001) Delta-9-tetrahydrocannabinol differentially supresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptors in the least shrew. Pharmacol Biochem Behav 69:239–249

    Article  CAS  PubMed  Google Scholar 

  102. Meiri E et al (2007) Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 23:533–543

    Article  CAS  PubMed  Google Scholar 

  103. Davis MP (2008) Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Investig Drugs 17:85–95

    Article  CAS  PubMed  Google Scholar 

  104. May MB, Grode AE (2016) Dronabinaol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics. Cancer Manag Res 8:49–55

    CAS  PubMed  PubMed Central  Google Scholar 

  105. Badowski ML (2017) A review of oral cannabinoids and medical marijuana for the treatment of CINV: a focus on pharmacokinetic variability and pharmacodynamics. Cancer Chemother Pharmacol 80:441–449

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Pillai AK et al (2011) Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving highly emetogenic chemotherapy. Pediatr Blood Cancer 56:234–238

    Article  PubMed  Google Scholar 

  107. Zick SM et al (2009) Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. Support Care Cancer 17:563–572

    Article  PubMed  Google Scholar 

  108. Ryan JL et al (2012) Ginger reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer 20:1479–1489

    Article  PubMed  Google Scholar 

  109. Bossi P et al (2016) Searching for evidence to support the use of ginger in the prevention of chemotherapy-induced nausea and vomiting. J Altern Complement Med 22:486–488

    Article  PubMed  PubMed Central  Google Scholar 

  110. Geling O, Eichler H (2005) Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289–1294

    Article  CAS  PubMed  Google Scholar 

  111. Navari RM (2016) Should behavioral therapy be used as the primary treatment to control anticipatory vomiting? HemeOnc Today 17:13

    Google Scholar 

  112. Navari RM (2017) Cancer patients at high risk for chemotherapy-induced nausea and vomiting – prediction assessments/tools. Expert Rev Qual Cancer Care 2:102–108

    Google Scholar 

  113. Zhang L et al (2017) A randomized phase 3 study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly Emetogenic chemotherapy (HEC). Ann Oncol 29:452–458. https://doi.org/10.1093/annonc/mdx698

    Article  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology Oncology, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA

    Rudolph M. Navari

  2. Experimental Therapeutics Program, UAB Comprehensive Cancer Center, Birmingham, AL, USA

    Rudolph M. Navari

Authors
  1. Rudolph M. Navari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rudolph M. Navari .

Editor information

Editors and Affiliations

  1. Division of Medical Oncology, Federal University of São Paulo (UNIFESP) & Hospital Israelita Albert Einstein, São Paulo, Brazil, Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal

    Ramon Andrade De Mello

  2. Oncology Department, Henry Dunant Hospital Center, Athens, Greece

    Giannis Mountzios

  3. Department of Biomedical Sciences and Medicine, Universidade do Algarve, Faro, Portugal

    Álvaro A. Tavares

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Navari, R.M. (2019). Chemotherapy Induced Nausea and Vomiting. In: De Mello, R., Mountzios, G., Tavares, Á. (eds) International Manual of Oncology Practice. Springer, Cham. https://doi.org/10.1007/978-3-030-16245-0_46

Download citation

Publish with us

Policies and ethics

Search

Navigation